Renea A. Taylor

Combining 177Lu-PSMA-617 radioligand therapy with PSCA-CAR T cells improves tumor control and survival in prostate cancer models by overcoming antigen heterogeneity and reshaping the immunosuppressive tumor microenvironment.

This study uses single-cell RNA sequencing to show that focal neuroendocrine differentiation (Focal NED) in prostate cancer is transcriptionally distinct, characterized by androgen receptor expression and unique transcriptional sub-populations.

This study shows PMR-116, a second-generation RiBi inhibitor, effectively targets high-MYC cancers without causing DNA damage, suggesting RiBi as a viable cancer therapy.